World's Best Scientists 2026 revealed!
Patrick Neven

Patrick Neven

D-Index & Metrics

Medicine

D-Index
102
Citations
44560
World Ranking
7576
National Ranking
85

Overview

Patrick Neven is affiliated with KU Leuven in Belgium and has contributed extensively to the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research primarily focuses on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Genetics, and Molecular Biology.

The researcher's work covers a range of topics including:

  • Advanced Breast Cancer Therapies
  • Breast Cancer Treatment Studies
  • HER2/EGFR in Cancer Research
  • Cancer Treatment and Pharmacology
  • Cancer Risks and Factors
  • Estrogen and related hormone effects
  • Cancer-related Molecular Pathways

Recent notable publications by Patrick Neven include:

  • "A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer," 2021, Nature Medicine
  • "Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial," 2022, Journal of Clinical Oncology
  • "Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial," 2022, The Lancet Oncology
  • "Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study," 2021, Annals of Oncology
  • "Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study," 2021, The Lancet Oncology

The researcher has frequent collaborations with colleagues including Hans Wildiers, Ann Smeets, Giuseppe Floris, Kevin Punie, and Ines Nevelsteen, reflecting a consistent network of co-authors contributing to their work.

Patrick Neven's research has been published across several prominent venues, such as:

  • Cancer Research
  • Annals of Oncology
  • Journal of Clinical Oncology
  • Clinical Cancer Research
  • ESMO Open

Best Publications

  • MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

    George W. Sledge;Masakazu Toi;Patrick Neven;Joohyuk Sohn

  • Association analysis identifies 65 new breast cancer risk loci

    Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley

  • Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

  • Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes

    Nasim Mavaddat;Kyriaki Michailidou;Kyriaki Michailidou;Joe Dennis;Michael Lush

  • Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

    Xiaohong R. Yang;Jenny Chang-Claude;Ellen L. Goode;Fergus J. Couch

  • The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial

    George W. Sledge;Masakazu Toi;Patrick Neven;Joohyuk Sohn

  • Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche

    John R.B. Perry;Felix Day;Cathy E. Elks;Patrick Sulem

  • Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer

    Kyriaki Michailidou;Jonathan Beesley;Sara Lindstrom;Sander Canisius

  • Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

    Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching

  • Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

    M. Piccart;G. N. Hortobagyi;M. Campone;K. I. Pritchard

  • Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98

    Giuseppe Viale;Meredith M. Regan;Eugenio Maiorano;Mauro G. Mastropasqua

  • A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer

    Ayse Bassez;Hanne Vos;Laurien Van Dyck;Giuseppe Floris

  • Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up

    Meredith M Regan;Patrick Neven;Anita Giobbie-Hurder;Aron Goldhirsch

  • Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair

    Felix R. Day;Katherine S. Ruth;Deborah J Thompson;Kathryn L. Lunetta

  • Genome-wide association studies identify four ER negative-specific breast cancer risk loci

    Montserrat Garcia-Closas;Fergus J. Couch;Sara Lindstrom;Kyriaki Michailidou

  • Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

    Giuseppe Viale;Anita Giobbie-Hurder;Meredith M. Regan;Alan S. Coates

  • Lasofoxifene in postmenopausal women with osteoporosis.

    Steven R. Cummings;Kristine E Ensrud;Pierre D. Delmas;Andrea Z. LaCroix

  • Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

    Stephen R D Johnston;Nadia Harbeck;Roberto Hegg;Masakazu Toi

  • Endometriosis and the development of malignant tumours of the pelvis. A review of literature

    Toon Van Gorp;Frederic Amant;Patrick Neven;Ignace Vergote

  • CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

    Meredith M. Regan;Brian Leyland-Jones;Mark Bouzyk;Olivia Pagani

Frequent Co-Authors

Hans Wildiers
Hans Wildiers KU Leuven
Hiltrud Brauch
Hiltrud Brauch German Cancer Research Center
Graham G. Giles
Graham G. Giles University of Melbourne
Roger L. Milne
Roger L. Milne Cancer Council Victoria
Jenny Chang-Claude
Jenny Chang-Claude German Cancer Research Center
Irene L. Andrulis
Irene L. Andrulis University of Toronto

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online education offers flexible and affordable ways to begin or advance a career in medicine and healthcare. For registered nurses seeking advancement, cheapest bsn programs online provide a cost-effective path to earn a bachelor's degree while balancing work and family commitments.

Those with a non-nursing background can consider direct entry msn programs for non-nursing majors online. These programs accelerate your route to a master’s degree in nursing, making a healthcare career accessible even without prior experience in the field.

Prospective students may also want to explore the easiest nursing programs to get into. These programs generally have flexible admissions criteria, increasing your chances of acceptance while still providing quality education.

If you’re drawn to the administrative side of healthcare, consider accredited courses in medical coding. Many of the medical billing and coding schools with financial aid offer online options, making it easier to start working in this vital aspect of medicine.

Best Scientists Citing Patrick Neven

Trending Scientists

Recently Published Articles